87: GLP-1 Price Cuts: Will It Improve Access?
Description
Send us a message with this link, we would love to hear from you. Standard message rates may apply.
We unpack new GLP-1 pricing, coverage hurdles, and whether cash-pay programs make these meds more reachable for diabetes, obesity, and sleep apnea care. Along the way we share candid pros and cons of injections, tease future oral options, and weigh real tradeoffs.
• current cash-pay pricing from major manufacturers
• differences between Wegovy, Ozempic, and Zepbound
• tighter insurance coverage and prior authorization burden
• fears about injections and route-of-administration bias
• potential oral GLP-1 timelines and cost impact
• framing obesity as a chronic, treatable disease
• practical tips to explore HSA or FSA options
• how to decide if the monthly cost is worth it
Production and Content: Edward Delesky, MD & Nicole Aruffo, RN
Artwork: Olivia Pawlowski
United States
